• Menu
    • Search
    • Stock Code: 00512.HK
    • About Us
      • Company Profile
      • Company History
      • Enterprise Members
    • Product Center
      • Pharmaceutical Preparations
      • Medical Devices
      • Bio-technology Products and Health Products
      • Specialized Pharmaceutical Raw Materials and Other Products
      • Innovative Pipeline
    • Investor Relations
      • Information Disclosure
      • Corporate Governance
      • Stock Info
      • Contact Information
    • News & Media
      • Corporate News
      • Media Reports
      • Monthly Newsletter
    • Contact Us
      • Contact Information
      • Privacy Protection
    • Language
      • EnglishEnglish
      • 繁体中文繁体中文
      • 简体中文简体中文
  • English English
    • EnglishEnglish
    • 繁体中文繁体中文
    • 简体中文简体中文
  • Stock Code: 00512.HK

Stock Infomation

  • Home
  • Stock Infomation
Contact Us

Units 3302, 33/F, The Center, 99 Queen's Road Central, Hong Kong

ir@chinagrandpharm.com

www.chinagrandpharm.com

Pages Links

Company Profile

Product Center

Investor Relations

News & Media

Stock Info

Contact Us

Privacy

Legal Statement

Recent News
  • GP (HK) Announces 2020 Annual Results Profit Attributable to Owners of the Company Significantly Increase 55.8% to HK$1,792.7 million Technological Innovation Drives the Internationalization Planning Multiple Material Investment and M&A Projects Proceed Steadily

    2021-3-19

  • SIR-Spheres® Y-90 Resin Microspheres Obtains Recommendation from NICE and Approval from the FDA to Conduct Clinical Trials on Primary Liver Cancer

    2021-3-9

© 2021. China Grand Pharmaceutical and Healthcare Holdings Limited All Rights Reserved.